Tag:

pharmaceuticals

Business

Ascletis to Present Data on Multiple Programs at the American Diabetes Association’s 2026 Scientific Sessions

by Chief Editor
written by Chief Editor

Ascletis Pharma Presents Promising Data for Novel Obesity Treatments at ADA 2026

Ascletis Pharma Inc. (HKEX: 1672) is set to present compelling preclinical and clinical data at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place June 5–8 in Recent Orleans, Louisiana. The presentations spotlight the company’s innovative pipeline of oral little molecule therapeutics targeting obesity and metabolic diseases.

ASC39: A Potential Game-Changer in Amylin Receptor Agonism

A late-breaking poster presentation will detail the preclinical data for ASC39, an oral small molecule amylin receptor agonist. According to the company, ASC39 demonstrates selectivity and potency comparable to eloralintide, a currently available amylin peptide analog. In head-to-head cyclic adenosine monophosphate (cAMP) activation assays, the EC50 for human amylin 1 receptor (hAMY1R) was 21.4 pM for ASC39 and 21.2 pM for eloralintide. Similarly, the EC50 for human calcitonin receptor (hCTR) was 846.1 pM and 1,350.8 pM, respectively, indicating similar selectivity for hAMY1R over hCTR.

From Instagram — related to Potential Game, Amylin Receptor Agonism

This is significant because amylin receptor agonists function by slowing gastric emptying, increasing satiety, and reducing food intake. The development of an oral small molecule agonist like ASC39 could offer a more convenient and potentially more accessible treatment option compared to injectable peptide analogs.

ASC30 Shows Promising Weight Loss and GI Tolerability

Data from a U.S. Phase II study of ASC30, an oral GLP-1R agonist, will also be presented. The study demonstrated a placebo-adjusted weight loss of 7.7% in participants with obesity. Importantly, ASC30 exhibited better gastrointestinal tolerability than orforglipron, with half the rate of vomiting observed during weekly titration.

GLP-1R agonists are a well-established class of drugs for weight management, but many currently available options require injection. An oral formulation with improved tolerability could broaden access and adherence to these therapies.

ASC37 Demonstrates Oral Bioavailability

Ascletis will also present data on ASC37, an oral tablet containing a GLP-1R/GIPR/GCGR triple agonist peptide. Nonhuman primate studies showed an average absolute oral bioavailability of 4.2%.

Even as 4.2% bioavailability may seem low, it represents a significant step forward for peptide-based therapeutics, which traditionally have very poor oral absorption. Ascletis’ Peptide Oral Transport ENhancement Technology (POTENT) appears to be playing a role in improving this delivery method.

The Rise of Oral Obesity Therapeutics

The data presented by Ascletis Pharma aligns with a broader trend in the pharmaceutical industry: the pursuit of effective and convenient oral therapies for obesity. Historically, obesity treatment has been limited by the need for injections or invasive procedures. The development of oral small molecule and peptide-based options is poised to revolutionize the field.

Webinar: Avidity Biosciences – EXPLORE44-OLE® Topline and Functional Data Presentation

The company is also developing ASC30_39 FDC, a fixed-dose combination of ASC30 and ASC39, expected to enter clinical development with an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the third quarter of 2026. This combination approach aims to leverage the complementary mechanisms of action of GLP-1R and amylin receptor agonists for enhanced weight loss and metabolic benefits.

Pro Tip:

Keep an eye on fixed-dose combination therapies. Combining different mechanisms of action in a single pill can often lead to synergistic effects and improved patient outcomes.

Pro Tip:
American Diabetes Association Scientific Sessions Present Data

Ascletis’ Technology Platforms

Ascletis Pharma’s success is built on its proprietary technology platforms, including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP). These technologies enable the company to efficiently identify and develop novel drug candidates with optimized properties.

FAQ

Q: What is an amylin receptor agonist?
A: An amylin receptor agonist is a type of medication that mimics the effects of amylin, a hormone naturally produced by the pancreas. It helps regulate appetite and food intake.

Q: What is a GLP-1R agonist?
A: A GLP-1R agonist is a medication that activates the glucagon-like peptide-1 receptor, leading to increased insulin secretion, decreased glucagon secretion, and slowed gastric emptying.

Q: When is Ascletis expected to submit an IND application for ASC30_39 FDC?
A: Ascletis expects to submit an IND application to the FDA in the third quarter of 2026.

Did you know? Ascletis Pharma is listed on the Hong Kong Stock Exchange (1672.HK).

To learn more about Ascletis Pharma and its pipeline, visit www.ascletis.com.

What are your thoughts on the potential of oral obesity treatments? Share your comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Nine tips to help choose over-the-counter medications safely and wisely – The Irish Times

by Chief Editor
written by Chief Editor

The Shift Toward Precision Self-Medication

For decades, the pharmacy aisle has been a “one size fits all” experience. You have a headache. you buy paracetamol. You have a cough; you reach for a codeine-based syrup. But the future of over-the-counter (OTC) medicine is moving toward pharmacogenomics—the study of how your genes affect your response to drugs.

Grab codeine as a prime example. As we know, the body converts codeine into morphine to relieve pain. However, not everyone’s liver processes this conversion at the same rate. “Ultra-rapid metabolizers” can experience dangerously high levels of morphine in their system from a standard dose, while “poor metabolizers” get no pain relief at all.

In the coming years, we expect to see a rise in affordable, at-home genetic testing kits. Imagine scanning a QR code on a medication box that cross-references your genetic profile to warn you: “Warning: Your body processes this ingredient too quickly. Consult a pharmacist for a safer alternative.”

Did you know? Some people are genetically unable to perceive the effects of codeine, leading them to accidentally overdose by taking more pills in a desperate attempt to find relief.

Digital Guardians: AI and the End of Medication Errors

The “common sense” approach to OTC safety is often flawed as humans are forgetful. We forget that the “multi-symptom” cold medicine we took this morning already contains paracetamol, and then we take a separate painkiller two hours later, risking liver toxicity.

The next frontier is the AI-integrated medicine cabinet. We are already seeing the emergence of smart apps that allow users to upload photos of their medication labels. These tools don’t just list ingredients; they use semantic AI to predict potential drug-drug interactions in real-time.

Future trends suggest a seamless integration between your wearable health tech (like an Apple Watch or Oura ring) and your OTC usage. If your heart rate is elevated or your blood pressure is spiking, a digital health assistant could warn you against using a pseudoephedrine-based decongestant, which is known to narrow blood vessels and increase blood pressure.

The “Behind-the-Counter” Movement and Stricter Regulation

There is a growing global trend toward reclassifying “low-risk” drugs. The memorandum from the Health Service Executive (HSE) regarding codeine is a harbinger of a larger shift. We are moving away from the “supermarket model” of pharmacy and back toward a “clinical model.”

Expect to see more “Pharmacy-Only” (P) medications—drugs that don’t require a prescription but must be dispensed by a pharmacist after a brief consultation. This prevents the “silent addiction” that occurs when people buy codeine-combination products from various stores to avoid suspicion.

This shift isn’t just about opioids. We are seeing similar scrutiny applied to nasal decongestants. The phenomenon of rhinitis medicamentosa—where the nasal lining becomes dependent on oxymetazoline, leading to permanent tissue damage—is prompting regulators to push for shorter pack sizes and mandatory warning labels regarding the “three-day limit.”

Pro Tip: When shopping for OTCs, always seem for the “active ingredients” list rather than the brand name. Many different brands use the exact same chemical, and buying the generic version often saves you money without sacrificing efficacy.

Beyond the Quick Fix: The Rise of Integrative Alternatives

As public awareness of the risks of long-term OTC use grows, there is a pivot toward integrative pharmacy. Instead of relying on a chemical nasal spray to clear sinuses for a month, patients are being steered toward saline irrigation and corticosteroid sprays which have a lower risk of rebound congestion.

We are also seeing a trend in “precision dosing.” Rather than a standard 500mg tablet, future OTCs may come in customizable delivery systems—such as dissolvable strips or precision-dose liquids—that allow users to take the absolute minimum effective dose, reducing the burden on the liver and kidneys.

For more on managing your health between visits, check out our guide on how to prepare a medication list for your GP to ensure no interaction goes unnoticed.

Frequently Asked Questions

Can I become addicted to OTC codeine?
Yes. Even low-dose codeine can lead to physical and psychological dependence if used for more than three consecutive days. Withdrawal symptoms can include anxiety, insomnia, and restlessness.

Why can’t I use nasal decongestant sprays for a week?
Overuse causes “rebound congestion.” The blood vessels in your nose swell more than before once the drug wears off, making you feel more congested and trapping you in a cycle of dependency.

Are “multi-symptom” medicines better than single-ingredient ones?
Usually, no. They often contain ingredients you don’t need, increasing the risk of side effects and the likelihood of accidentally doubling up on a specific drug (like paracetamol).

Who should I consult before starting a new OTC medication?
Always consult a licensed pharmacist. They are the most accessible healthcare experts and can check for interactions with your existing prescriptions via World Health Organization safety standards.

Join the Conversation

Have you ever experienced a surprising side effect from a common OTC drug, or do you have a tip for staying safe while self-medicating? Share your story in the comments below or subscribe to our newsletter for more evidence-based health insights.

Subscribe for Health Updates

0 comments
0 FacebookTwitterPinterestEmail
Health

Amyloid drugs for Alzheimer’s debate heats up

by Chief Editor
written by Chief Editor

The battle over how we treat Alzheimer’s disease has reached a fever pitch. On one side, we have the gold-standard rigor of the Cochrane review, suggesting that clearing amyloid plaques from the brain is like painting a house while the foundation is crumbling—it looks better on a scan, but the structure is still failing. On the other, leading clinicians argue that we are witnessing the “chemotherapy moment” of dementia care: the first, modest steps of a revolution.

For families and patients, this academic tug-of-war isn’t just about data points; it’s about hope, timing, and the definition of a “meaningful” recovery.

The Great Amyloid Debate: Are We Targeting the Right Thing?

For decades, the “amyloid hypothesis” has dominated neuroscience. The theory is simple: beta-amyloid plaques build up in the brain, disrupting cell communication and leading to cognitive decline. If you remove the plaques, you stop the disease.

From Instagram — related to Amyloid, Dementia

However, recent findings have thrown a wrench in this logic. Some researchers argue that by the time plaques are visible on a PET scan, the damage is already done. They suggest that the modest slowing of decline seen in newer drugs like lecanemab and donanemab doesn’t justify the risks of brain swelling or microbleeds (known as ARIA).

“The real question isn’t whether these drugs work—they do remove plaque—but whether removing plaque actually saves the person.”

But here is where the nuance lies. Experts from the Australian Dementia Network (ADNeT) point out a critical flaw in the skeptical view: comparing today’s precision medicine to the failed attempts of a decade ago. It’s like dismissing modern targeted cancer therapy because the first attempts at chemotherapy in the 1940s were toxic and ineffective.

Did you know? Dementia is now the leading cause of death in Australia. With cases projected to more than double by 2065, the pressure to move from “managing” to “treating” the disease has never been higher.

The Shift Toward “Combination Therapy”

If you look at the history of HIV/AIDS, the breakthrough didn’t come from a single “miracle drug.” It came from the “cocktail”—combining different antiretrovirals to attack the virus from multiple angles. We are likely heading toward a similar future for Alzheimer’s.

Future trends suggest that anti-amyloid therapies will be just one piece of the puzzle. We are seeing a move toward treating the disease as a multi-system failure, targeting:

  • Tau Protein: Preventing the “tangles” that kill neurons from the inside.
  • Neuro-inflammation: Calming the brain’s overactive immune response.
  • Vascular Health: Improving blood flow to ensure the brain gets the oxygen it needs to function.

By combining these approaches, the “modest” benefit of current drugs could transform into a significant preservation of independence and memory.

The Game-Changer: Blood-Based Biomarkers

Perhaps the most exciting trend isn’t the drug itself, but how we find the patients who need them. Traditionally, diagnosing Alzheimer’s required expensive PET scans or invasive lumbar punctures. This meant many patients were diagnosed too late—after the brain had already suffered irreversible atrophy.

MultiPark Debate | Alzheimer’s disease | Aducanumab: YES or NO?

Enter blood tests for Alzheimer’s. New diagnostic tools are being trialed that can detect amyloid and tau levels with a simple blood draw. This allows for “pre-symptomatic” intervention. If we can treat the brain before the memory loss begins, the efficacy of these drugs could skyrocket.

Pro Tip for Caregivers: Early detection is everything. If you notice subtle changes in a loved one’s ability to plan, organize, or remember recent conversations, don’t dismiss it as “just vintage age.” Request a referral to a neurologist specifically to discuss the latest biomarker screening options.

Balancing Risk, Cost, and Quality of Life

As these therapies move toward wider availability, the conversation is shifting from “Does it work?” to “Is it worth it?”

For some, slowing cognitive decline by 27% over 18 months is a miracle—it might mean six more months of recognizing a grandchild’s face or staying independent in their own home. For others, the risk of brain bleeds and the high cost of treatment (often not covered by government subsidies like the PBS in Australia) make the trade-off unattractive.

This creates a “nuanced landscape” for clinicians. The future of dementia care will not be a one-size-fits-all prescription, but a highly personalized plan based on a patient’s genetic profile, their specific type of plaque buildup, and their personal values regarding risk.

Frequently Asked Questions

Do anti-amyloid drugs cure Alzheimer’s?

No. Currently, no drug cures Alzheimer’s. These therapies are designed to slow the progression of the disease, effectively “buying time” for the patient.

What are the main side effects of these new treatments?

The most significant risks are ARIA (Amyloid-Related Imaging Abnormalities), which can manifest as brain swelling or modest hemorrhages. Most cases are asymptomatic, but some can be serious.

When will blood tests for Alzheimer’s be available?

Many are already in clinical trial phases and some are being used in specialized clinics. Widespread availability depends on regulatory approval and healthcare system integration.

Join the Conversation on Brain Health

The landscape of dementia care is changing every month. Do you believe modest slowing of decline is a victory, or should we be looking for a complete cure? Let us know in the comments below or subscribe to our newsletter for the latest updates on neurodegenerative research.

Stay Informed

0 comments
0 FacebookTwitterPinterestEmail
News

Trump nominates Erica Schwartz as CDC director

by Rachel Morgan News Editor
written by Rachel Morgan News Editor

President Donald Trump has nominated Erica Schwartz to serve as the director of the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent leader of the agency.

Schwartz, who must be confirmed by the Senate, will enter the role as Health and Human Services Secretary Robert F. Kennedy Jr. Manages a series of controversial health policy changes. These changes include a significant overhaul of childhood vaccine recommendations.

A Background in Public Health and Military Service

Schwartz previously served as the deputy surgeon general during the first Trump administration, where she held a major role in the U.S. Response to the Covid-19 pandemic. She spent over 20 years in uniform, including service as a rear admiral and the chief medical officer of the Coast Guard.

According to official records, she holds a medical degree from Brown University and a law degree from the University of Maryland. She previously worked for 24 years in the Commissioned Corps of the US Public Health Service.

Did You Know? Under the federal Vacancies Act, an acting officer can only serve in place of a Senate-confirmed official for a maximum of 210 days.

Agency Turmoil and Leadership Shifts

The nomination follows a period of intense instability at the CDC. Dr. Jay Bhattacharya had been serving as the acting director, but his legal authority to do so expired last month under the Vacancies Act.

Agency Turmoil and Leadership Shifts
Secretary Kennedy Secretary Kennedy

The most recent confirmed director, Dr. Susan Monarez, served for less than a month last summer. In September, Monarez testified to Congress that she was fired after refusing demands from Secretary Kennedy to approve vaccine recommendations she believed lacked scientific support.

Beyond leadership disputes, the agency has struggled with plummeting morale and significant staff turnover. This environment was further strained by a gunman’s attack on the CDC’s Atlanta headquarters on August 8.

Expert Insight: The appointment of a nominee with a deep military and deputy surgeon general background may be a strategic move to instill discipline and stability in an agency currently reeling from internal upheaval and public trust deficits.

Controversies Over Vaccine Policy

The CDC is currently navigating a contentious shift in immunization policy. Last month, a judge blocked the efforts of a critical vaccine panel to reduce the number of recommended childhood shots from 17 to 11.

These policy shifts coincide with a decline in public confidence. A February poll from the health policy research group KFF indicates that trust in federal health agencies has plummeted across the political spectrum during Secretary Kennedy’s tenure.

Expanding the CDC Leadership Team

Alongside Schwartz, President Trump announced two other key appointments for the agency. Sean Slovenski has been chosen as the deputy CDC director and chief operating officer.

Trump nominates Erica Schwartz, former deputy surgeon general, to serve as CDC director

Jennifer Shuford will serve as the deputy CDC director and chief medical officer. Shuford previously led the Texas Department of State Health Services, where she credited vaccination and testing with ending a massive measles outbreak last year.

Potential Next Steps

The confirmation process in the Senate will likely be a critical next step in establishing permanent leadership. Depending on the outcome, the agency may spot a continued push for the policy overhauls championed by Secretary Kennedy.

It remains to be seen how Schwartz’s specific views on vaccines could align with or diverge from the current direction of the HHS Secretary.

Frequently Asked Questions

Who is Erica Schwartz?

Erica Schwartz is a former deputy surgeon general and a retired Coast Guard rear admiral and chief medical officer. She holds degrees in medicine from Brown University and law from the University of Maryland.

From Instagram — related to Erica Schwartz, Schwartz

Why was the previous CDC director fired?

Dr. Susan Monarez stated in congressional testimony that she was fired after refusing to approve vaccine recommendations demanded by Secretary Robert F. Kennedy Jr., which she believed lacked scientific support.

What is the current state of trust in the CDC?

According to a February poll by KFF, trust in federal health agencies has plummeted across the political spectrum during the tenure of HHS Secretary Robert F. Kennedy Jr.

How do you believe a permanent director will affect the current stability of federal health agencies?

0 comments
0 FacebookTwitterPinterestEmail
Health

AI analyzes Reddit posts to find underreported GLP-1 side effects

by Chief Editor
written by Chief Editor

The Rise of ‘Computational Social Listening’: How AI is Uncovering Hidden Drug Side Effects

For decades, identifying drug side effects relied heavily on clinical trials and post-market reporting. Now, a new approach is gaining traction: analyzing the vast ocean of patient experiences shared on social media. Researchers at the University of Pennsylvania have pioneered a method using artificial intelligence to sift through hundreds of thousands of online posts, revealing potential side effects of popular weight-loss drugs like semaglutide and tirzepatide (GLP-1s) that may be underreported through traditional channels.

Beyond Clinical Trials: The Power of Patient Voices

Clinical trials, although essential, have limitations. They often involve a specific demographic and may not capture the full spectrum of side effects experienced by a broader population over a longer period. “Clinical trials generally identify the most dangerous side effects of drugs,” explains Lyle Ungar, Professor in Computer and Information Science at Penn. “But they can fail to locate what symptoms patients are most concerned about.” Social media, with its real-time sharing of experiences, offers a complementary source of information.

Beyond Clinical Trials: The Power of Patient Voices

The Penn team analyzed over 400,000 Reddit posts from nearly 70,000 users over five years, published in Nature Health. This “computational social listening,” as the researchers call it, isn’t about replacing clinical trials, but augmenting them. “This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight,” says Sharath Chandra Guntuku, Research Associate Professor at Penn Engineering.

Uncovering Underreported Symptoms: Reproductive Health and Temperature Fluctuations

The AI analysis confirmed many known side effects, like nausea, validating the method’s accuracy. Yet, it also highlighted two areas of concern that warrant further investigation: reproductive symptoms and temperature-related complaints. Nearly 4% of Reddit users reported menstrual irregularities, a figure the researchers believe is significant, particularly within a female-only sample. Users also described experiencing chills, hot flashes, and fever-like symptoms.

Fatigue also emerged as a frequently reported complaint, despite not consistently reaching reporting thresholds in clinical trials. Jena Shaw Tronieri, Senior Research Investigator at Penn’s Center for Weight and Eating Disorders, notes that GLP-1s engage the hypothalamus, a brain region regulating hormones, potentially explaining these reports. “That doesn’t mean the medications are necessarily causing these symptoms, but it could suggest that reports of menstrual changes and body temperature fluctuations are worth studying more systematically.”

The Role of Large Language Models

Historically, analyzing social media for health insights was a laborious process. Mapping user-described symptoms to standardized medical terminology (MedDRA) was time-consuming and limited the scale of analysis. The advent of large language models (LLMs) like GPT and Gemini has revolutionized this process. These models can now analyze vast amounts of text quickly and standardize language, making large-scale “computational social listening” feasible.

Future Trends: Expanding the Scope of Social Media Surveillance

The Penn team’s work signals a broader trend: the increasing apply of AI to monitor online platforms for early warning signs of drug-related issues. This approach isn’t limited to prescription medications. Researchers suggest it could be particularly valuable for tracking substances that gain rapid popularity online, especially those sold in loosely regulated markets, like injectable peptides.

Looking ahead, the team plans to expand their analysis beyond Reddit and English-language communities. “We don’t really know yet whether what we’re seeing on Reddit reflects the experience of GLP-1 users globally, or whether it’s particular to the kind of person who posts on Reddit in the United States,” Ungar explains. The goal is to create a more comprehensive and representative picture of patient experiences.

FAQ

Q: Can we definitively say GLP-1s *cause* these unreported symptoms?
A: No. The study identifies correlations, not causation. Further research is needed to establish a direct link.

Q: Is Reddit representative of the general population?
A: No. Reddit users tend to be younger, more male, and disproportionately based in the United States. However, the large sample size provides valuable signals for further investigation.

Q: How does this research support patients?
A: By highlighting potential side effects that may not be widely known, it empowers patients to discuss these concerns with their doctors and make informed decisions about their health.

Q: What is ‘computational social listening’?
A: It’s the process of using AI to analyze large volumes of social media data to identify trends and patterns related to health and medication experiences.

Did you know? Online patient communities can act like a “neighborhood grapevine,” sharing experiences that often don’t make it into formal medical reports.

Pro Tip: If you’re experiencing side effects from a medication, document them carefully and discuss them with your healthcare provider, even if they aren’t listed as common side effects.

Want to learn more about the latest advancements in AI and healthcare? Explore our other articles and subscribe to our newsletter for updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program

by Chief Editor
written by Chief Editor

Ecuador’s Bold Move Towards Rabies Elimination: A Blueprint for Global Health Security

Ecuador is making significant strides towards becoming only the second country in Latin America to eliminate dog-mediated rabies, following Mexico’s lead. This ambitious goal, guided by the Pan American Health Organization (PAHO), centers on mass dog vaccination, robust epidemiological surveillance, and accessible post-exposure prophylaxis. The initiative, announced at the international One Health Summit, highlights a growing global focus on proactive disease prevention and cross-sector collaboration.

The Three Pillars of Ecuador’s Rabies-Free Future

The Ecuador Free of Rabies project, coordinated by the Ministry of Public Health and implemented with Boehringer Ingelheim’s Stop Rabies program, is built on three core strategies:

The Three Pillars of Ecuador’s Rabies-Free Future

Strengthened Surveillance: A Robust Health Response System

A key component of the project is bolstering Ecuador’s national health surveillance system. Improved detection, reporting, and coordination between health services and diagnostic laboratories are crucial for managing suspected cases effectively. PAHO notes that strengthening rabies surveillance can also enhance broader public health capacities, including monitoring other zoonotic diseases like malaria, zika, chikungunya, and dengue.

Education and Public Awareness: Reaching a Generation

The project aims to educate four million children within the National Education System by 2030. This involves community outreach programs focused on responsible pet ownership, proactive prevention, and appropriate responses to potential rabies exposure. Raising awareness is vital, as rabies is almost always fatal once clinical symptoms appear.

Vaccination: The Cornerstone of Prevention

Ecuador has maintained a remarkable record, with no reported dog-to-human rabies transmission since 2006, thanks to over 20 years of dedicated immunization efforts. The project reinforces the importance of vaccinating over 80% of the dog population – a threshold identified by PAHO as essential for interrupting the transmission cycle and achieving elimination.

One Health in Action: A Global Trend

Ecuador’s initiative exemplifies the “One Health” approach, recognizing the interconnectedness of human, animal, and environmental health. This collaborative model is gaining traction globally, particularly in the wake of the COVID-19 pandemic, which exposed critical gaps in global health security. The World Health Summit and events like the Foreign Policy-hosted discussions in Berlin are spotlighting the need for cross-sector partnerships to drive innovation and build resilience against future health threats.

The Role of Pharmaceutical Companies and Sustainable Development

Boehringer Ingelheim’s support for Ecuador’s project, and its broader Stop Rabies program launched in 2022, demonstrates a growing commitment from the pharmaceutical industry to address global health challenges. This commitment is embedded within Boehringer Ingelheim’s Sustainable Development for Generations strategy, focusing on vaccination, education, and surveillance. The company’s 40+ years of experience in rabies prevention underscores the value of long-term investment and expertise.

Future Trends in Rabies Elimination

Several trends are poised to accelerate rabies elimination efforts worldwide:

  • Advanced Surveillance Technologies: The integration of digital tools and data analytics will enable more rapid and accurate disease tracking, allowing for targeted interventions.
  • Improved Vaccine Delivery Systems: Innovative approaches, such as drone-based vaccine delivery in remote areas, could significantly increase vaccination coverage.
  • Community-Based Programs: Empowering local communities to participate in surveillance, vaccination, and education efforts will be crucial for sustained success.
  • Increased Cross-Sector Collaboration: Stronger partnerships between governments, NGOs, pharmaceutical companies, and local communities will be essential for coordinating resources and maximizing impact.

FAQ: Rabies Elimination

What is rabies? Rabies is a viral disease that affects the central nervous system, almost always leading to death once symptoms appear.

How is rabies transmitted? The vast majority of human rabies cases are caused by dog bites.

Can rabies be prevented? Yes, rabies is 100% preventable through vaccination of dogs and timely post-exposure prophylaxis in humans.

What is the “Zero by 30” initiative? It’s a global goal to end human deaths from dog-mediated rabies by 2030.

What role does Boehringer Ingelheim play in rabies elimination? Boehringer Ingelheim supports rabies elimination through its Stop Rabies program, focusing on vaccination, education, and surveillance.

Did you know? Dogs are the source of over 99% of human rabies infections globally.

Pro Tip: If bitten by an animal, wash the wound thoroughly with soap and water and seek immediate medical attention.

Learn more about Boehringer Ingelheim’s commitment to animal health and sustainable development at www.boehringer-ingelheim.com.

What are your thoughts on Ecuador’s approach to rabies elimination? Share your comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

To lower drug prices, give PBMs a fiduciary duty to patients

by Chief Editor
written by Chief Editor

The Shifting Landscape of Pharmacy Benefit Managers: Accountability and Transparency on the Horizon

For years, concerns have mounted regarding the role of pharmacy benefit managers (PBMs) in the prescription drug supply chain. Accusations of prioritizing profits over patient access and affordability have been widespread. Now, a confluence of Congressional action and Department of Labor (DOL) initiatives signals a potential turning point, aiming to align PBM incentives with those of employers and patients.

The PBM Model Under Scrutiny

PBMs act as intermediaries between health insurers, employers, and pharmaceutical companies. They negotiate drug prices, create formularies (lists of covered drugs), and process claims. However, the complexity of these arrangements has often lacked transparency, leading to questions about how rebates and discounts are utilized.

Research indicates that while PBMs negotiate, the benefits haven’t consistently translated to savings for payers or patients. A study highlighted that PBMs’ share of insulin expenditures nearly tripled between 2014 and 2018 without corresponding overall savings. Increased rebates have been linked to higher list prices, ultimately increasing out-of-pocket costs for individuals whose cost-sharing is tied to those list prices.

Recent Legislative and Regulatory Developments

The enactment of the Inflation Reduction Act of 2022 authorized the federal government to negotiate lower drug prices with manufacturers for some drugs covered by Medicare. More recently, the Consolidated Appropriations Act (CAA) mandated a broad framework for PBM transparency, making them the most transparent actor in the prescription drug supply chain.

Building on this momentum, in January 2026, the Department of Labor proposed a rule focused on improving transparency into PBM fee disclosure. This proposal aims to shed light on PBM practices and ensure fair pricing. However, the Pharmaceutical Care Management Association (PCMA) has urged the DOL to rescind the proposed rule, arguing it duplicates requirements already established in the CAA and imposes unnecessary burdens.

What’s Next for PBMs? Potential Future Trends

Several key trends are likely to shape the future of PBMs:

  • Increased Fiduciary Responsibility: A significant shift is the potential for PBMs to be held legally accountable as fiduciaries. This would require them to act in the best interests of their clients (employers and health plans) and beneficiaries (patients).
  • Enhanced Transparency: The CAA and the DOL’s proposed rule (despite challenges to its implementation) are driving a demand for greater transparency in PBM operations. Expect more detailed reporting on fees, rebates, and spread pricing (the difference between what a PBM pays a pharmacy and what it bills the health plan).
  • Rise of Pass-Through PBMs: A growing number of employers are opting for “pass-through” PBM arrangements, where all rebates and discounts are directly passed on to the plan sponsor, eliminating potential conflicts of interest.
  • Vertical Integration Challenges: The trend of PBMs acquiring or partnering with pharmacies and other healthcare providers will likely face increased scrutiny to ensure fair competition and prevent anti-competitive practices.

Impact on Patients and Employers

These changes have the potential to deliver significant benefits:

  • Lower Drug Costs: Increased transparency and negotiation power could lead to lower net drug costs for employers and patients.
  • Improved Access to Medications: More equitable formulary design and reduced administrative burdens could improve patient access to necessary medications.
  • Greater Plan Sponsor Control: Employers and health plans will have more insight into PBM operations and greater control over their pharmacy benefits.

FAQ

  • What is spread pricing? Spread pricing is the difference between what a PBM pays a pharmacy for a drug and what it bills the health plan.
  • What does it mean for PBMs to be fiduciaries? It means they are legally obligated to act in the best interests of their clients and beneficiaries.
  • Will these changes immediately lower my prescription drug costs? The impact will likely be gradual as new regulations are implemented and contracts are renegotiated.

Pro Tip: Employers should actively review their PBM contracts and consider requesting a full audit of PBM performance to ensure they are receiving the best possible value.

Did you realize? The Department of Labor’s proposed rule follows a similar approach to state-level PBM regulations already in place in several states.

Stay informed about the evolving landscape of pharmacy benefit management and advocate for policies that prioritize affordability and access to essential medications. Explore additional resources on the Department of Labor’s Employee Benefits Security Administration (EBSA) website for the latest updates and guidance.

0 comments
0 FacebookTwitterPinterestEmail
Business

Eli Lilly reaches deal to bring AI-developed drugs to global market

by Chief Editor
written by Chief Editor

AI Revolutionizes Drug Discovery: Lilly’s $2.75 Billion Bet on Insilico

The pharmaceutical industry is undergoing a seismic shift, driven by the rapid advancements in artificial intelligence. This week, Eli Lilly took a massive leap forward, announcing a $2.75 billion deal with Hong Kong-based Insilico Medicine to accelerate the development of AI-discovered drugs. This collaboration isn’t just about money; it’s a strategic alignment poised to reshape how medicines are created.

The Power of Generative AI in Pharma

Insilico Medicine is at the forefront of generative AI in drug discovery. The company has already developed at least 28 drug candidates using these tools, with nearly half currently in clinical trials. This represents a significant acceleration compared to traditional drug development timelines. Generative AI allows scientists to design molecules with specific properties, potentially leading to more effective and targeted therapies.

A Deepening Partnership

This $2.75 billion agreement builds upon an existing relationship. The two companies initially partnered in 2023 with an AI-based software licensing agreement. The new deal will provide Insilico with an upfront payment of $115 million, with the remaining funds tied to achieving regulatory and commercial milestones, as well as future sales royalties. Insilico will also be integrated into Lilly’s Gateway Labs community, fostering further collaboration and innovation.

Lilly’s Strategic Vision

Eli Lilly’s investment signals a clear commitment to AI-driven drug discovery. According to Alex Zhavoronkov, CEO of Insilico, Lilly possesses unique strengths in integrating biology, chemistry, and automation. Zhavoronkov noted that Lilly “is better than us in some areas of AI,” highlighting the value of combining Insilico’s AI platform with Lilly’s established infrastructure and expertise. This partnership allows both companies to leverage their respective strengths for maximum impact.

China’s Role in AI Drug Development

While Insilico develops its AI algorithms in Canada and the Middle East, a portion of its early preclinical drug development is conducted in China. This strategic location allows for faster research and potentially lower costs. Lilly’s recent announcement of a $3 billion investment in China further underscores the country’s growing importance in the global pharmaceutical landscape. Currently, China accounts for slightly less than 3% of Lilly’s total revenue.

What Which means for the Future

This deal is indicative of a broader trend: pharmaceutical companies are increasingly recognizing the potential of AI to revolutionize drug discovery. AI can not only accelerate the process but also reduce costs and improve the success rate of drug development. Expect to see more collaborations between AI-driven biotech companies and established pharmaceutical giants in the coming years.

Pro Tip

Keep an eye on companies investing heavily in AI and automation. These are likely to be the leaders in the next generation of pharmaceutical innovation.

FAQ

Q: What is generative AI in drug discovery?
A: Generative AI uses algorithms to design new molecules with desired properties, accelerating the identification of potential drug candidates.

Q: How much money is involved in the Lilly-Insilico deal?
A: The deal is worth up to $2.75 billion, with $115 million paid upfront.

Q: Where does Insilico conduct its AI research?
A: Insilico develops its AI algorithms in Canada and the Middle East.

Q: What is Lilly’s Gateway Labs?
A: Lilly’s Gateway Labs is a community for biotech development, and Insilico will be joining it as part of this collaboration.

Q: What percentage of Lilly’s revenue comes from China?
A: Slightly less than 3% of Lilly’s revenue came from China last year.

Did you understand? Insilico Medicine’s shares have risen more than 50% year-to-date, reflecting investor confidence in the company’s AI-driven approach.

Want to learn more about the intersection of AI and pharmaceuticals? Explore additional resources on CNBC and Insilico Medicine’s website.

0 comments
0 FacebookTwitterPinterestEmail
Health

Pharma & Biotech Moves: Averna Therapeutics Hires CSO Robert Mabry | STAT News

by Chief Editor
written by Chief Editor

Averna Therapeutics Bolsters Leadership: What It Signals for the Future of Gene Therapy

Averna Therapeutics’ recent appointments of Robert Mabry as Chief Scientific Officer (CSO) and Richard Morris as Chief Financial Officer (CFO) aren’t just internal shifts; they represent a strategic move within the rapidly evolving landscape of genomic medicine. These hires, announced on March 26, 2026, signal a heightened focus on translating cutting-edge science into viable, scalable therapies.

The Rise of Gene Insertion Technology

Averna Therapeutics is focused on gene insertion technology, a critical area within gene therapy. Traditional viral-based gene therapies, while promising, face limitations in payload size and potential immune responses. Non-viral approaches, like Averna’s, aim to overcome these hurdles. The company’s approach utilizes RNA instructions that convert to stable DNA, delivered via lipid nanoparticles (LNPs). This method offers the potential for broader applicability and customizable treatments.

The appointment of Dr. Mabry, with his background at Hillstar Bio and Takeda Pharmaceuticals, is particularly noteworthy. His experience leading Hillstar Bio, focused on precision immunotherapy, suggests a potential convergence of gene editing and immune modulation strategies. This is a growing trend, as researchers explore ways to enhance the efficacy and specificity of gene therapies.

Why Now? The Growing Demand for Genomic Medicine Expertise

The biotech industry is experiencing a surge in demand for leaders with expertise in genomic medicine. Several factors are driving this trend. First, the success of early gene therapies has validated the approach, attracting significant investment. Second, advancements in technologies like CRISPR and RNA-based therapies are expanding the possibilities. Third, the increasing understanding of the genetic basis of disease is creating a larger pipeline of potential targets.

Richard Morris’s appointment as CFO underscores the financial complexities of developing and commercializing these advanced therapies. Building a financially sustainable genomic medicines company requires a leader with a proven track record in corporate finance and company building – precisely Morris’s expertise.

The Role of Site-Specific Retrotransposons

Averna’s specific approach centers on site-specific retrotransposons, naturally occurring genetic elements that insert DNA into “safe harbor” locations within the genome. This minimizes the risk of disrupting essential cellular functions, a major concern with earlier gene editing techniques. Leveraging these natural systems, combined with RNA and LNP delivery, represents a potentially transformative strategy.

Did you know? Retrotransposons have evolved over billions of years to efficiently and safely insert genetic material, offering a blueprint for engineered gene insertion systems.

Looking Ahead: Potential Trends in Genomic Medicine

Several key trends are likely to shape the future of genomic medicine:

  • Increased Focus on Non-Viral Delivery: Expect continued innovation in non-viral delivery systems, like LNPs, to improve safety and scalability.
  • Convergence of Gene Editing and Immunotherapy: Combining gene editing with immune modulation strategies to create more targeted and effective therapies.
  • Personalized Genomic Medicine: Tailoring gene therapies to individual patients based on their genetic profiles.
  • Expansion of Addressable Diseases: Moving beyond rare genetic disorders to tackle more common diseases with a genetic component.

FAQ

Q: What is gene insertion technology?
A: Gene insertion technology aims to introduce new or missing genetic instructions into cells to treat disease, offering a potential alternative to traditional gene editing approaches.

Q: What are lipid nanoparticles (LNPs)?
A: LNPs are tiny particles used to deliver genetic material, like RNA, into cells.

Q: What are retrotransposons?
A: Retrotransposons are naturally occurring genetic elements that can insert DNA into the genome, and Averna is leveraging them for safe and precise gene insertion.

Pro Tip: Keep an eye on companies like Averna Therapeutics, as they are at the forefront of developing innovative gene therapy technologies.

Want to learn more about the latest advancements in genomic medicine? Visit Averna Therapeutics’ website to explore their platform and pipeline.

0 comments
0 FacebookTwitterPinterestEmail
Health

White House Drafts Drug Pricing Legislation, Shares with Pharma Companies

by Chief Editor
written by Chief Editor

Trump Administration Pushes for Legislative Drug Pricing Reform

Washington D.C. – The White House is actively working to translate its voluntary drug pricing agreements with pharmaceutical companies into formal legislation. Officials are currently sharing draft legislative text with over a dozen major pharmaceutical companies, signaling a continued commitment to lowering prescription drug costs.

Building on Voluntary Agreements

The proposed legislation closely mirrors the framework of the deals already struck with companies like Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk. These initial agreements focused on linking U.S. Drug prices to those paid in other developed nations – a “most favored nation” (MFN) policy. The new legislative text aims to codify this approach and expand its reach.

Cash Payments and Deductibles: A Key Component

A significant element of the draft legislation involves allowing payments made in cash for prescriptions to count towards a patient’s annual deductible. This provision could incentivize patients to seek lower cash prices, potentially increasing competition and driving down overall costs. Currently, many insurance plans do not credit cash payments towards deductibles.

Broader Healthcare Reform Efforts

The push for drug pricing legislation is part of a larger effort by the Trump administration to achieve comprehensive healthcare reform. With an election year underway, the President is prioritizing affordability initiatives, elevating the profile of these efforts. This suggests a strategic move to address a key voter concern.

Nine Additional Pharma Companies Join the Effort

In December 2025, President Trump announced agreements with nine additional biopharmaceutical companies: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These companies have committed to lowering prices on drugs treating conditions like type two diabetes, rheumatoid arthritis, and certain cancers.

Tariff Relief as Incentive

A key incentive for pharmaceutical companies to participate in these agreements is a three-year grace period from potential pharmaceutical-specific tariffs. The administration has used the threat of tariffs as leverage to secure price concessions. Companies are also committing to invest at least $150 billion collectively in U.S. Manufacturing.

Strategic API Reserve Strengthened

Three of the companies involved in the drug pricing deals – Amgen, Bristol Myers Squibb, and Boehringer Ingelheim – are donating active pharmaceutical ingredients (APIs) for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This aims to reduce reliance on foreign nations and ensure a stable supply of essential medications within the United States.

Impact on Medicaid Programs

The agreements will provide access to MFN drug prices on products made by the nine companies to every State Medicaid program, potentially resulting in billions of dollars in savings for the program and its beneficiaries.

Future Trends and Implications

The move towards legislative action suggests a long-term strategy to reshape the pharmaceutical pricing landscape. Further developments could include:

Increased Transparency

Pressure for greater transparency in drug pricing is likely to continue. Legislative efforts may focus on requiring pharmaceutical companies to disclose more information about their pricing decisions and research and development costs.

Expansion of MFN Pricing

The MFN policy could be expanded to cover a wider range of drugs and potentially applied to other healthcare services.

Continued Use of Tariff Leverage

The administration may continue to use the threat of tariffs as a negotiating tactic to secure lower drug prices from companies that are reluctant to participate in voluntary agreements.

FAQ

Q: What is the “most favored nation” (MFN) pricing policy?
A: It aims to link U.S. Drug prices to the lowest prices paid in other developed nations.

Q: How will the cash payment provision affect patients?
A: It could allow patients who pay cash for prescriptions to apply those payments towards their annual deductibles.

Q: What is the role of tariffs in these agreements?
A: Pharmaceutical companies receive a three-year grace period from potential tariffs in exchange for agreeing to lower drug prices and invest in U.S. Manufacturing.

Q: Which companies have reached agreements with the Trump administration?
A: Agreements have been reached with AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.

Did you know? Approximately 30% to 40% of drugs sold to Medicaid currently have prices higher than those paid in other nations.

Pro Tip: Patients should always compare prices at different pharmacies and explore available discount programs to find the lowest possible cost for their medications.

Stay informed about the latest developments in healthcare policy. Explore our other articles on drug pricing and healthcare reform to gain a deeper understanding of these complex issues.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts